$BOLT News
Last published 1w ago
- 1w agoBOLTBolt Biotherapeutics to Participate in Upcoming ConferencesGlobeNewswireREDWOOD CITY, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) ("Bolt" or the "Company"), a clinical-stage biotechnology company pioneering a new generation of
- 2w agoBOLTBolt Therapeutics Conference Call - BOLT BIOTHERAPEUTICS INCEarnings Call TranscriptsGood morning and welcome to the Bolt Biotherapeutics conference call and webcast. Please note that this call is being recorded and will be available for replay on boltbio.com. All participants are in a listen-only mode.
- 2w agoBOLTBolt Therapeutics Conference Call - BOLT BIOTHERAPEUTICS INCEarnings Call TranscriptsGood morning and welcome to the Bolt Biotherapeutics conference call and webcast. Please note that this call is being recorded and will be available for replay on boltbio.com. All participants are in a listen-only mode.
- 2w agoBOLTBolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory IndicationsGlobeNewswireTransactions position the company to advance Prana’s pipeline of next-generation, half-life-extended multispecific antibodies enabled by its proprietary INSPIRE platformPRA-216 is a novel IL-4Rα/TSLP bispecific antibody
- 6mo agoBOLTBolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireFirst-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected in 3Q 2026 Cash balance of $23.9 million as of March 31, 2026 anticipated to fund operations into
- 8mo agoBOLTBolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business UpdateGlobeNewswireFirst-in-class immune-stimulating antibody conjugate BDC-4182 in Phase 1 dose escalation study, initial clinical data expected in 3Q 2026 Cash balance of $31.8 million as of December 31, 2025 anticipated to fund key
- 8mo agoBOLTBolt Biotherapeutics to Participate in Upcoming March ConferencesGlobeNewswireREDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that
- 12mo agoBOLTBolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireInitial clinical data for BDC-4182 Phase 1 dose escalation study expected in 3Q 2026 Cash balance of $38.8 million as of September 30, 2025 anticipated to fund key milestones into 2027 REDWOOD CITY, Calif., Nov. 12,
- 1y agoBOLTBolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027GlobeNewswireInitial clinical data for BDC-4182 Phase 1 dose escalation study now expected in 3Q 2026Company is implementing a 50% workforce reduction to extend cash runway into 2027 REDWOOD CITY, Calif., Oct. 01, 2025 (GLOBE
- 1y agoBOLTBolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireNext-generation claudin 18.2 ISAC BDC-4182 now in Phase 1 dose-escalation study Cash balance of $48.5 million as of June 30, 2025 anticipated to fund key milestones through mid-2026 REDWOOD CITY, Calif., Aug. 14,
- 1y agoBOLTBolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireBDC-4182 Phase 1 dose-escalation study now open for enrollmentBDC-3042 Phase 1 dose-escalation data presented at AACR 2025 demonstrated a favorable safety profile, dose-dependent biological activity, and monotherapy
- 1y agoBOLTBolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate UpdatesGlobeNewswireConference call and webcast on Monday, May 12, 2025, at 2:30 p.m. PT / 5:30 p.m. ET REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a biopharmaceutical company developing
- 1y agoBOLTBolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025GlobeNewswireCEA-targeted ISAC elicits complete responses in mice and is well-tolerated in NHPs PD-L1 ISAC directly activates and reprograms PD-L1-expressing myeloid cells in the TME to drive complete responses and immunological
- 1y agoBOLTBolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025GlobeNewswireBDC-3042 was well tolerated up to 10 mg/kg q2w with no dose-limiting toxicities and no drug-related serious adverse events BDC-3042 showed biological activity, with clear dose-dependent increases in proinflammatory
- 1y agoBOLTBolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025GlobeNewswireREDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced it
- 1y agoBOLTBolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business UpdateGlobeNewswireBDC-4182 on track to start a clinical trial in gastric cancer in second quarter 2025BDC-3042 Phase 1 clinical trial fully enrolled the highest dose cohort with no dose-limiting toxicities (DLTs), results will be reported
- 1y agoBOLTBolt Biotherapeutics to Participate in Upcoming March ConferencesGlobeNewswireREDWOOD CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that
- 1y agoBOLTBolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.GlobeNewswire-- Targeting Unmet Needs for Treating Solid Tumors-- REDWOOD CITY, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc., announced today that the target of their worldwide co-development collaboration
- 1y agoBOLTBolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswireAdvanced to the highest dose level in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancersPresented updated preclinical activity of BDC-4182 and key learnings from Phase 1
- 2y agoBOLTBolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual MeetingGlobeNewswireBDC-4182 demonstrated compelling anti-tumor activity and an acceptable safety profile in preclinical studies BDC-4182 outperformed cytotoxic claudin 18.2 ADCs in syngeneic model Learnings from BDC-1001 data suggest
- 2y agoBOLTBolt Biotherapeutics Announces Changes to its Board of DirectorsGlobeNewswireREDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the
- 2y agoBOLTINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BoltPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bolt Biotherapeutics, Inc. ("Bolt" or the...
- 2y agoBOLTDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BoltGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Bolt To Contact Him Directly To Discuss Their Options If you suffered losses
- 2y agoBOLTBolt Biotherapeutics to Participate in Upcoming September ConferencesGlobeNewswireREDWOOD CITY, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that
- 2y agoBOLTINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BoltPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bolt Biotherapeutics, Inc. ("Bolt" or the...
- 2y agoBOLTSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BoltPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bolt Biotherapeutics, Inc. ("Bolt" or the...
- 2y agoBOLTBolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswireAdvanced to Cohort 6 in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancersAbstract accepted for BDC-4182, a claudin 18.2-targeting BoltbodyTM ISAC at the Society for Immunotherapy of
- 2y agoBOLTDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BoltPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bolt Biotherapeutics, Inc. ("Bolt" or the...
- 2y agoBOLTDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BoltPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bolt Biotherapeutics, Inc. ("Bolt" or the...
- 2y agoBOLTFaruqi & Faruqi LLP Reminds Shareholders of a Lead Plaintiff Deadline on September 3, 2024 in Bolt LawsuitPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bolt Biotherapeutics, Inc. ("Bolt" or the...
- 2y agoBOLTSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BoltGlobeNewswireSecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Bolt To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Bolt between February 5,
- 2y agoBOLTSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BoltPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bolt Biotherapeutics, Inc. ("Bolt" or the...
- 2y agoBOLTBolt Biotherapeutics, Inc. (BOLT) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoBOLTBolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership TeamGlobeNewswireRefocusing pipeline to Phase 1 Dectin-2 agonist antibody BDC-3042 and next-generation Boltbody™ ISAC platform including new clinical candidate BDC- 4182 targeting Claudin 18.2Bolt to cease further development of
- 2y agoBOLTBolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateGlobeNewswire– BDC-1001 (trastuzumab imbotolimod) Phase 2 studies in four HER2-positive tumor types advancing toward 2024 milestones– BDC-3042 Phase 1 study successfully cleared safety assessments in the first three dose level
- 2y agoBOLTBolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare ConferenceGlobeNewswireREDWOOD CITY, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that
- 2y agoBOLTPCRXPacira Appoints Frank D. Lee as Chief Executive OfficerGlobeNewswire-- Transformational Leader Brings Three Decades of Global Experience in Pharmaceutical and Biotechnology Product Development and Commercialization -- -- Paul J. Hastings Named Chair of the Board -- -- Dave Stack to
- 2y agoBOLTBolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®GlobeNewswireBDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in Phase 2 development for HER2-positive breast, colorectal, endometrial, and gastroesophageal cancersPoster detailing trial design and
- 3y agoBOLTBolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewswireBDC-1001 program advances in multiple Phase 2 clinical studies in patients with HER2-positive colorectal, gastric, endometrial, and metastatic breast cancer, with recent updated data at ESMO showing improved clinical
- 3y agoBOLTBolt Biotherapeutics to Present at Stifel 2023 Healthcare ConferenceGlobeNewswireREDWOOD CITY, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that
- 3y agoACHLADVMAVIRBOLT+610 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An AnalysisACCESS NewswireNEW YORK, NY / ACCESSWIRE / October 24, 2023 / The biotech sector, known for its exponential growth potential, is currently facing highly challenging market conditions. Influences like rising inflation, geopolitical
- 3y agoBOLTBolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 CongressGlobeNewswireUpdated safety data supports the selection of 20 mg/kg q2w as the recommended Phase 2 dose (RP2D)Improved efficacy with one partial response (PR) improving to a complete response (CR), two additional patients with
- 3y agoBOLTBolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer's 2023 Annual MeetingGlobeNewswireCompany to debut preclinical data illustrating how the combination of trastuzumab ISAC and pertuzumab augments anti-tumor efficacy in multiple HER2+ tumor models relative to trastuzumab plus pertuzumabCompany announces
- 3y agoBOLTBolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced CancersGlobeNewswireBDC-3042, a novel Dectin-2 agonistic antibody that stimulates the innate immune system, is being evaluated in a Phase 1/2 dose-escalation and expansion study in patients with a broad range of solid tumors REDWOOD CITY,
- 3y agoBOLTBolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023GlobeNewswireREDWOOD CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (NASDAQ:BOLT), a clinical-stage biopharmaceutical company pioneering novel immuno-oncology therapeutics for the treatment of cancer,
- 3y agoBOLTBolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric CancersGlobeNewswireBDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in Phase 2 development for HER2-positive breast, colorectal, endometrial, and gastroesophageal cancersThe FDA granted BDC-1001 Orphan Drug
- 3y agoBOLTBolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042GlobeNewswireREDWOOD CITY, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, announced
- 3y agoBOLTBolt Biotherapeutics to Participate in September Investor ConferencesGlobeNewswireREDWOOD CITY, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that
- 3y agoBOLTBolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive CancerGlobeNewswireBDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in development for HER2-positive breast, colorectal, endometrial, and gastroesophageal cancersBDC-1001 administered to initial patients in Phase
- 3y agoBOLTBolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023GlobeNewswireREDWOOD CITY, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today